VCA
ACAD icon

Verdence Capital Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Verdence Capital Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-15,077
Closed -$230K – 265
2018
Q2 		$230K Buy
15,077
+2,500
+20% +$44.6K 0.06% 249
2018
Q1 		$283K Hold
12,577
– – 0.07% 227
2017
Q4 		$379K Buy
+12,577
New +$402K 0.09% 183

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Verdence Capital Advisors's ACAD Position: Q3 2018 in Review

Verdence Capital Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2018, closing a stake of 15,077 shares — an estimated $230K sold.

Verdence Capital Advisors first reported a position in ACAD in Q4 2017 and held it in 3 quarters. The position peaked at $379K in Q4 2017. 184 funds tracked by Wall St. Rank hold ACAD as of Q3 2018.

  • Verdence Capital Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Verdence Capital Advisors sold 15,077 Acadia Pharmaceuticals shares in Q3 2018, an estimated $230K.
  • Verdence Capital Advisors first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Verdence Capital Advisors's Acadia Pharmaceuticals position peaked at $379K in Q4 2017.
  • 184 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2018.

Based on Verdence Capital Advisors's 13F filing for Q3 2018, filed 25 Feb 2020.